Rose Ong
YOU?
Author Swipe
View article: Characteristics, Treatment Patterns and Outcomes of Patients with Pulmonary Arterial Hypertension by Race and Ethnicity Using Real-World Data from the Combined OPUS/OrPHeUS Studies
Characteristics, Treatment Patterns and Outcomes of Patients with Pulmonary Arterial Hypertension by Race and Ethnicity Using Real-World Data from the Combined OPUS/OrPHeUS Studies Open
gov .
View article: Comorbid Depression and Anxiety Risk in Older Individuals with Geographic Atrophy: A US Claims Data Analysis
Comorbid Depression and Anxiety Risk in Older Individuals with Geographic Atrophy: A US Claims Data Analysis Open
This study found a higher risk for comorbid depression or anxiety in patients with GA versus propensity score-matched controls. Risk was greatest among those with bilateral GA with subfoveal involvement. These findings highlight the import…
View article: Rehabilitation of functional neurological disorder with lower limb powered robotic exoskeleton: A case report
Rehabilitation of functional neurological disorder with lower limb powered robotic exoskeleton: A case report Open
Rationale: Functional neurological disorder (FND) is a disabling and challenging condition that straddles Neurology and Psychiatry. Prolonged symptoms in FND are associated with poor functional outcome. Multidisciplinary management often i…
View article: Macitentan and Tadalafil Combination Therapy in Incident and Prevalent Pulmonary Arterial Hypertension: Real-World Evidence from the OPUS/OrPHeUS Studies
Macitentan and Tadalafil Combination Therapy in Incident and Prevalent Pulmonary Arterial Hypertension: Real-World Evidence from the OPUS/OrPHeUS Studies Open
Despite a historically worse prognosis, incident patients receiving M+T, including as initial combination therapy, had similar survival and hospitalization as prevalent patients. Safety profiles were similar across cohorts. Together, these…
View article: Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset
Macitentan in Pulmonary Arterial Hypertension Associated with Connective Tissue Disease (CTD-PAH): Real-World Evidence from the Combined OPUS/OrPHeUS Dataset Open
The above graphical abstract represents the opinions of the authors. For a full list of declarations, including funding and author disclosure statements, and copyright information, please see the full text online. (see “read the peer-revi…
View article: Predictors of outcomes in mild pulmonary hypertension according to 2022 ESC/ERS Guidelines: the EVIDENCE-PAH UK study
Predictors of outcomes in mild pulmonary hypertension according to 2022 ESC/ERS Guidelines: the EVIDENCE-PAH UK study Open
Background and Aims Interventional studies in pulmonary arterial hypertension completed to date have shown to be effective in symptomatic patients with significantly elevated mean pulmonary artery pressure (mPAP) (≥25 mmHg) and pulmonary v…
View article: Mortality rates and cause of mortality in patients with mildly elevated pulmonary pressures versus PH: insights from the retrospective EVIDENCE-PAH study
Mortality rates and cause of mortality in patients with mildly elevated pulmonary pressures versus PH: insights from the retrospective EVIDENCE-PAH study Open
Background Normal mean pulmonary artery pressure (mPAP) does not exceed 20 mmHg and normal pulmonary vascular resistance (PVR) does not exceed 2 Wood Units (WU). The thresholds used to define pre-capillary pulmonary hypertension (PH) – mPA…
View article: Concomitant initiation of combination therapy with macitentan and tadalafil in pulmonary arterial hypertension (PAH) patients with comorbidities: real-world data from OPUS and OrPHeUS
Concomitant initiation of combination therapy with macitentan and tadalafil in pulmonary arterial hypertension (PAH) patients with comorbidities: real-world data from OPUS and OrPHeUS Open
Background Guidelines for the management of pulmonary arterial hypertension (PAH) recommend early combination therapy of an endothelial receptor antagonist (ERA) and a phosphodiesterase type-5 inhibitor (PDE5i) [1]. There is, however, limi…
View article: Epidemiology and Treatment Patterns of Pulmonary Arterial Hypertension (PAH) Patients Across US Regions Using Real-World Data from OPUS/OrPHeUS
Epidemiology and Treatment Patterns of Pulmonary Arterial Hypertension (PAH) Patients Across US Regions Using Real-World Data from OPUS/OrPHeUS Open
Rationale: Management of PAH in the US is decentralized, with potential healthcare differences across regions.We used real-world data from OPUS/OrPHeUS to describe PAH patient characteristics and treatment patterns across four US regions.M…
View article: Treatment Patterns in Patients with Incident Parkinson’s Disease in the United States
Treatment Patterns in Patients with Incident Parkinson’s Disease in the United States Open
Time from diagnosis to treatment start was relatively short, suggesting that PD diagnosis, as reflected in the database, is closely linked to start of symptomatic treatment. Levodopa treatment remains the most common treatment, especially …